Latest Ratios: P/E Ratio -13.5x · EV/EBITDA N/A · ROE -64.8%. (2018–2026 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.9B | $4.5B | $2.6B | $4.5B | $1.9B | $604M | $1.4B | $673M | — | — |
| Enterprise Value | $6.0B | $3.6B | $1.9B | $3.8B | $1.5B | $113M | $1.0B | $575M | — | — |
| P/E Ratio → | -13.49 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 966.12 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 7.11 | 5.31 | 3.66 | 7.22 | 5.27 | 1.29 | 3.60 | 7.15 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -64.8% | -64.8% | -62.5% | -52.9% | -50.7% | -36.4% | -44.3% | -141.1% | -1.8% | — |
| ROA | -58.3% | -58.3% | -57.4% | -48.4% | -45.8% | -33.8% | -41.2% | -120.9% | -0.2% | -120827.1% |
| ROIC | — | — | — | — | — | — | — | — | — | — |
| ROCE | -68.3% | -68.3% | -66.1% | -55.1% | -50.0% | -36.1% | -44.3% | -126.8% | -1.8% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 12.22 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 31.41 | — |
| Net Debt / Equity | — | -1.06 | -1.01 | -1.03 | -1.04 | -1.05 | -1.01 | -1.04 | -1.02 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | -2.62 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -15.90 | — | — | -105.07 | — | — |
Net cash position: cash ($902M) exceeds total debt ($72000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.09 | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 0.85 | 0.07 |
| Quick Ratio | 9.09 | 9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 0.85 | 0.07 |
| Cash Ratio | 8.64 | 8.64 | 10.38 | 13.07 | 8.70 | 11.09 | 21.32 | 6.57 | 0.85 | — |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $182M | $152M | $138M | $123M | $110M | $88M | $43M | $14M | $10M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IMVT stock.
Immunovant, Inc.'s current P/E ratio is -13.5x. This places it at the 50th percentile of its historical range.
Immunovant, Inc.'s return on equity (ROE) is -64.8%. The historical average is -56.8%.
Based on historical data, Immunovant, Inc. is trading at a P/E of -13.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Continued cash burn dependence
Metrics are mathematically derived from official filings.
Valuation Reflects Pipeline Optionality Not Earnings
Based on reported figures, IMVT trades at a trailing P/E of -14.23 and a price-to-sales multiple above 1,000, reflecting a market price anchored to pipeline value rather than any current earnings or revenue base that could support conventional comparison.
The negative trailing P/E and absence of forward or EV-based multiples indicate that conventional earnings-based valuation is not meaningful for this pre-revenue company. The 7.50 price-to-book ratio versus a peer range spanning roughly 3.0 to 8.3 suggests the market is paying a premium over book value for the clinical portfolio, which investors may view as embedding a high probability of successful Phase 3 readouts. Valuation therefore appears to hinge on pipeline probability assumptions rather than on observable financial performance, warranting close monitoring of catalyst timing.
Net Margins Deeply Negative Across Quarters
As reported in financial statements, IMVT's operating margin of -21.6% in 2027Q1 and return on equity of -14.0% to -27.7% across recent quarters indicate losses that remain large relative to both revenue and shareholder capital.
With revenue essentially absent in most quarters, margin ratios are structurally distorted and should be read as indicators of cost scale rather than operating efficiency. The 2027Q1 margin profile, where a 100% gross margin sits alongside negative operating and net margins, suggests the fixed R&D base overwhelms any incremental revenue. Operating losses appear driven by development spending, so earning power is better judged through cash burn and pipeline milestones than through margin trends.
Return Metrics Remain Persistently Negative
Based on reported figures, IMVT's ROIC of -26.5% in 2026Q2 and -59.6% in 2026Q1, alongside ROA between -12.1% and -23.7%, show capital being consumed rather than compounded over the ten-quarter window.
Negative ROIC and ROA across the period indicate that invested capital is generating losses rather than returns, a pattern typical of clinical-stage biotechs but one that offers no evidence of decay reversing. The variance between the -59.6% and -26.5% ROIC readings suggests the denominator and loss trajectory are both shifting quarter to quarter. Returns will likely remain negative until a commercial product generates sustained earnings, so investors should treat these ratios as measures of burn intensity.
Ample Liquidity Buffer Masks Burn Rate
As reported in financial statements, IMVT's current ratio of 7.31 in 2027Q2 and 9.09 at year-end 2026 indicate a substantial short-term liquidity cushion, though this buffer shrinks relative to roughly $1.0B of cumulative negative free cash flow.
A current ratio above 7 implies that current liabilities are small relative to liquid assets, supporting near-term solvency without any debt service pressure. However, liquidity ratios capture a point-in-time snapshot and do not reflect the trajectory of cash depletion. Investors should weigh the strong current ratio against the cash balance decline from $902.1M to $722.3M, as the headline cushion may appear more comfortable than the underlying runway warrants.
Debt-Free Balance Sheet Shifts Risk to Equity
According to recent SEC filings, IMVT reported a debt-to-equity ratio of 0.00 in 2026Q4 and 2025Q4 with no interest coverage applicable, meaning the solvency risk is concentrated in equity dilution rather than debt service.
The absence of leverage removes refinancing and covenant exposure, which is a structural strength for a company without commercial revenue. Because losses are eroding shareholders' equity, the zero debt position effectively means future funding will likely come through dilutive equity issuance. The balance sheet therefore appears to trade one form of risk for another, and monitoring of financing announcements is warranted.
Headline Ratios Mislead on Pre-Revenue Economics
Based on reported figures, the 7.31 current ratio and zero debt-to-equity may appear reassuring, but these metrics obscure a cash burn exceeding $1.0B over ten quarters that conventional ratios do not capture.
Ratios like the current ratio and P/E are most commonly misapplied to pre-revenue biotechs because they assume a stable earnings base that does not yet exist. A high current ratio reflects cash on hand, not the duration of that cash against burn, so a more appropriate lens is cash runway measured as cash divided by trailing quarterly free cash flow burn. Investors should also weigh the pipeline's probability-adjusted value against book value, since the 7.50 price-to-book ratio is driven largely by intangible optionality rather than tangible assets.